ADMA Biologics, Inc.
ADMANASDAQHealthcare● Active
$8.06
+$0.09(+1.19%)
Market Cap$1.9B
P/E Ratio—
52W High$22.37
52W Low$7.21
ADMA Biologics, Inc. (ADMA) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ADMA · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 6, 2026EPS Actual
$0.19
Est. $0.19 · -1.7%
Revenue
$0.11B
Est. $0.14B · -18.2%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 6, 2026
After Market Close
▼ Miss EPS▼ Miss Revenue
ADMA reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.27B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.27B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 5, 2026 | $0.19 | — | — | — | $0.13B | — |
| ▼ Q2 FY2026 | May 6, 2026 | $0.19 | $0.19 | -1.7% | $0.11B | $0.14B | -18.2% |
| ▲ Q1 FY2026 | Feb 25, 2026 | $0.18 | $0.20 | +8.1% | $0.14B | $0.14B | -0.3% |
| — Q4 FY2025 | Nov 5, 2025 | $0.16 | $0.16 | +0.0% | $0.13B | $0.14B | -4.0% |
| ▲ Q3 FY2025 | Aug 6, 2025 | $0.14 | $0.15 | +7.1% | $0.12B | $0.13B | -6.4% |
| ▼ Q2 FY2025 | May 7, 2025 | $0.16 | $0.14 | -12.5% | $0.11B | $0.12B | -5.8% |
| ▼ Q1 FY2025 | Mar 3, 2025 | $0.15 | $0.14 | -6.7% | $0.12B | $0.11B | +8.2% |
| ▲ Q4 FY2024 | Nov 7, 2024 | $0.13 | $0.15 | +15.4% | $0.12B | $0.11B | +5.7% |
Q3 FY2026
Aug 5, 2026
EPS Actual
—
EPS Est.
$0.19
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 6, 2026Miss
EPS Actual
$0.19
EPS Est.
$0.19
EPS Surpr.
-1.7%
Revenue
$0.11B
Q1 FY2026
Feb 25, 2026Beat
EPS Actual
$0.20
EPS Est.
$0.18
EPS Surpr.
+8.1%
Revenue
$0.14B
Q4 FY2025
Nov 5, 2025
EPS Actual
$0.16
EPS Est.
$0.16
EPS Surpr.
+0.0%
Revenue
$0.13B
Q3 FY2025
Aug 6, 2025Beat
EPS Actual
$0.15
EPS Est.
$0.14
EPS Surpr.
+7.1%
Revenue
$0.12B
Q2 FY2025
May 7, 2025Miss
EPS Actual
$0.14
EPS Est.
$0.16
EPS Surpr.
-12.5%
Revenue
$0.11B
Q1 FY2025
Mar 3, 2025Miss
EPS Actual
$0.14
EPS Est.
$0.15
EPS Surpr.
-6.7%
Revenue
$0.12B
Q4 FY2024
Nov 7, 2024Beat
EPS Actual
$0.15
EPS Est.
$0.13
EPS Surpr.
+15.4%
Revenue
$0.12B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.33 | $0.36 | $0.41 | 1 |
| Q3 FY2027 | $0.27 | $0.30 | $0.34 | 1 |
| Q2 FY2027 | $0.25 | $0.27 | $0.31 | 1 |
| Q1 FY2027 | $0.22 | $0.24 | $0.28 | 1 |
| Q4 FY2026 | $0.23 | $0.26 | $0.29 | 1 |
| Q3 FY2026 | $0.19 | $0.21 | $0.25 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.2B | $0.2B | $0.2B | 1 |
| Q3 FY2027 | $0.2B | $0.2B | $0.2B | 2 |
| Q2 FY2027 | $0.2B | $0.2B | $0.2B | 2 |
| Q1 FY2027 | $0.2B | $0.2B | $0.2B | 1 |
| Q4 FY2026 | $0.2B | $0.2B | $0.2B | 2 |
| Q3 FY2026 | $0.1B | $0.1B | $0.2B | 3 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 6, 2026 | -1.7% | $10.25 | $10.08 | -1.66% |
| ▲ Q1 FY2026 | Feb 25, 2026 | +8.1% | $15.52 | $15.68 | +1.03% |
| ▲ Q4 FY2025 | Nov 5, 2025 | +0.0% | $14.63 | $15.37 | +5.06% |
| ▲ Q3 FY2025 | Aug 6, 2025 | +7.1% | $18.96 | $18.54 | -2.22% |
| ▼ Q2 FY2025 | May 7, 2025 | -12.5% | $23.12 | $23.61 | +2.12% |
| ▼ Q1 FY2025 | Mar 3, 2025 | -6.7% | $16.39 | $15.83 | -3.42% |
| ▲ Q4 FY2024 | Nov 7, 2024 | +15.4% | $19.67 | $19.72 | +0.25% |
| ▲ Q3 FY2024 | Aug 8, 2024 | +62.5% | $11.45 | $12.19 | +6.46% |
Q2 FY2026-1.66%
Report Date
May 6, 2026
EPS Beat/Miss
-1.7%
Price Before
$10.25
Price After
$10.08
Q1 FY2026+1.03%
Report Date
Feb 25, 2026
EPS Beat/Miss
+8.1%
Price Before
$15.52
Price After
$15.68
Q4 FY2025+5.06%
Report Date
Nov 5, 2025
EPS Beat/Miss
+0.0%
Price Before
$14.63
Price After
$15.37
Q3 FY2025-2.22%
Report Date
Aug 6, 2025
EPS Beat/Miss
+7.1%
Price Before
$18.96
Price After
$18.54
Q2 FY2025+2.12%
Report Date
May 7, 2025
EPS Beat/Miss
-12.5%
Price Before
$23.12
Price After
$23.61
Q1 FY2025-3.42%
Report Date
Mar 3, 2025
EPS Beat/Miss
-6.7%
Price Before
$16.39
Price After
$15.83
Q4 FY2024+0.25%
Report Date
Nov 7, 2024
EPS Beat/Miss
+15.4%
Price Before
$19.67
Price After
$19.72
Q3 FY2024+6.46%
Report Date
Aug 8, 2024
EPS Beat/Miss
+62.5%
Price Before
$11.45
Price After
$12.19
Avg Beat Reaction+2.12%
Avg Miss Reaction-0.99%
Beat Rate5 / 8 quarters
Largest Move+6.46% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ADMA ends December
ADMA Biologics, Inc. (ADMA) most recently reported earnings on May 6, 2026 for Q2 FY2026, posting EPS of $0.19 — missing the analyst consensus of $0.19 by -1.7%. The next ADMA earnings date is expected around September 1, 2026.
Each quarter, investors track ADMA earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ADMA revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ADMA's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ADMA earnings · 5 questionsADMA Biologics, Inc.'s next earnings report is expected around September 1, 2026. ADMA typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ADMA historically reports after market close (AMC).
ADMA earnings datewhen is ADMA earningsADMA next earnings datewhen does ADMA report earningsADMA earnings calendar
▸ Source: FMP · ADMA Biologics, Inc. SEC filings · US GAAP · ADMA Biologics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026